# Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Study · id `cardio:ct-nct02132234` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02132234](<https://clinicaltrials.gov/study/NCT02132234>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02132234

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT02132234. Randomized; triple masking; primary purpose treatment. Start 2013-06 (registry gives no type); primary completion 2014-07 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT02132234, source copy `cardio:ctgov-nct02132234-2014-05-07`, retrieved 2026-10-26)
- Start date: 2013-06 (registry gives no type) (ClinicalTrials.gov record NCT02132234, source copy `cardio:ctgov-nct02132234-2014-05-07`, retrieved 2026-10-26)
- Primary completion: 2014-07 (anticipated) (ClinicalTrials.gov record NCT02132234, source copy `cardio:ctgov-nct02132234-2014-05-07`, retrieved 2026-10-26)
- Completion: Not reported
- Countries: Poland (ClinicalTrials.gov record NCT02132234, source copy `cardio:ctgov-nct02132234-2014-05-07`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02132234-2014-05-07`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
- Condition: Rheumatoid Arthritis
- Condition: Psoriatic Arthritis
- Condition: Ankylosing Spondylitis
- Condition: Hypertension
- Intervention (Drug): Etanercept
- Intervention (Drug): Adalimumab
- Intervention (Drug): Certolizumab
- Intervention (Drug): Infliximab
- Lead sponsor: Jagiellonian University
- Lead sponsor class: OTHER
- Collaborator: Departmet of Rheumatology, J Dietl Hospital, Krakow, Poland
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Jagiellonian University (`cardio:org-jagiellonian-university`)

## Provenance

Content hash: 55d706b0626edeac325393d738a59d3921fc5f8e4c0d2bd51998aec0bbdd5483
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
